Aspen Online Webinar July 14-16, 2020
Below I’ve included some of my notes and slides. There may be errors of omission or transcription.
What’s Hot? NAFLD and NASH Stavra Xanthakos
- Fatty liver disease burden of NAFLD and NASH is increasing. This increases the rate of cirrhosis, liver cancer and liver transplantation; the latter is being needed at younger ages
- Explained that “Lean” (normal BMI) NAFLD is common
- Diabetes is strongest risk factor for severe fatty liver disease (NASH or fibrosis). PNPLA3 is genetic risk factor for NAFLD risk.
- Discussed treatment, particularly diet and bariatric surgery. Stated that some emerging treatments look promising.
- In those with suspected NAFLD, Dr. Xanthokos recommends liver biopsy, if lifestyle therapy is ineffective, under specific circumstances: prior to bariatric surgery, in some cases to determine severity, and prior to instituting therapy (eg Vitamin E)
Related blog posts:
- The Paramount Health Challenge for Humans in the 21st Century
- How Often Do Children with Obesity Have a Fatty Liver?
- Pediatric NAFLD: You Don’t Have to be Obese/Overweight to have Fatty Liver Disease (but it helps)
- Should Teenagers with Severe NAFLD Undergo Bariatric Surgery?
- Concise Review: Fatty Liver in Pediatrics
- Reaching Consensus on Bariatric Intervention in Children …
- Is a Three Year-Old Too Young for Bariatric Surgery …
- Should We Be Excited About a New Medication (Liraglutide …
- Overlooking Obesity in Hospitalized Children | gutsandgrowth
- Treating diabetes with surgery | gutsandgrowth
Pingback: Best Practice for Fatty Liver Disease | gutsandgrowth
Pingback: Is Fatty Liver Increased in Pediatric Population with Type 1 Diabetes Mellitus? | gutsandgrowth
Pingback: Increased Cancers with Fatty Liver Disease | gutsandgrowth
Pingback: Why It Is Hard to Stop Immunosuppression with Autoimmune Hepatitis and Lower Bone Density with Fatty Livers | gutsandgrowth
Pingback: Hepatic Steatosis as an Incidental Finding | gutsandgrowth
Pingback: Aspen Webinar 2021 Part 2 -Nonalcoholic Steatohepatitis | gutsandgrowth
Pingback: Losartan: Not Effective for Pediatric NAFLD | gutsandgrowth